Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.70 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.65 |
| ▸ | OSBP | P22059 | 1/20 | 0.65 |
| ▸ | RORC | P51449 | 1/20 | 0.65 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.65 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.58 |
| ▸ | NPC1L1 | Q9UHC9 | 1/20 | 0.58 |
| ▸ | GBA1 | P04062 | 2/20 | 0.58 |
| ▸ | UGCG | Q16739 | 2/20 | 0.58 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190539 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL767706 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL162885 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL22620094 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL21177689 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL412985 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL140321 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL18006649 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL295638 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 | |
| SCHEMBL9436821 | 1.00 | POLA1 (0.70) | POLA1CYP46A1USP2LMNAABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12233034-B2 | Formulations for epidermal repair | CLARIDEI LABORATORIES, INC. (US) | 2025-02-25 | — | — | US | claimed |
| CN-118086186-B | Use of ethyl stearate in combination with cholesterol myristate | 广州中医药大学(广州中医药研究院) | 2024-08-02 | — | — | CN | claimed |
| CN-118141908-A | Lymph targeting tumor nano vaccine and application thereof | 中国药科大学 | 2024-06-07 | — | — | CN | claimed |
| CN-118086184-A | Application of tortoise plastron extract combined with cholesterol myristate | 广州中医药大学(广州中医药研究院) | 2024-05-28 | — | — | CN | claimed |
| CN-118086186-A | Use of ethyl stearate in combination with cholesterol myristate | 广州中医药大学(广州中医药研究院) | 2024-05-28 | — | — | CN | claimed |
| CN-115851087-B | Blue light diffusion prevention coating and application thereof | 广东粤港澳大湾区黄埔材料研究院 | 2023-10-10 | — | — | CN | claimed |
| CN-115851087-A | Blue light diffusion preventing coating and application thereof | 广东粤港澳大湾区黄埔材料研究院 | 2023-03-28 | — | — | CN | claimed |
| EP-4025660-A1 | THERMOCHROMIC LIQUID CRYSTAL INKS AND COATINGS | Sun Chemical Corporation (US) | 2022-07-13 | — | — | EP | claimed |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CLARIDEI LABORATORIES, INC. | 2022-02-03 | — | — | US | claimed |
| CN-113679689-A | Compositions and methods for nanoparticle lyophilisate form | 日东电工株式会社 | 2021-11-23 | — | — | CN | claimed |
| US-20180289642-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | CLARIDEI LABORATORIES, INC. | 2018-10-11 | — | — | US | claimed |
| US-20160184245-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | CLARIDEI LABORATORIES, INC. | 2016-06-30 | — | — | US | claimed |
| EP-3024438-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | Eberting, Cheryl Lee (US) | 2016-06-01 | — | — | EP | claimed |
| EP-2853264-A1 | Nanodispersion | Sun Pharma Advanced Research Company Limited (IN) | 2015-04-01 | — | — | EP | claimed |
| WO-2015013634-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | EBERTING CHERYL LEE (US) | 2015-01-29 | — | — | WO | claimed |
| US-20060115445-A1 | Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents | L'OREAL S.A. (FR) | 2006-06-01 | — | — | US | claimed |
| EP-1647259-A1 | use for treatment of keratinic materials of compositions comprising electrophilic monomers and agents forming liquid crystals | L'OREAL (FR) | 2006-04-19 | — | — | EP | claimed |
| US-6328910-B1 | FOR IN SITU FORMATION OF AN POLYMERIC CYANOACRYLATE FILM ON MAMMALIAN SKIN WHICH CAN BE USED TO MONITOR THE SURFACE SKIN TEMPERATURE OF MAMMAL | MEDLOGIC GLOBAL CORPORATION | 2001-12-11 | — | — | US | claimed |
| US-5885565-A | APPLYING TO THE EPITHELIUM OF THE HOST, AN EFFECTIVE AMOUNT OF ONE OR MORE PENETRATION ENHANCING EPITHELIAL STEROLS AND THERAPEUTICAL OR PROPHYLACTIC AGENT | CELLEGY PHARMACEUTICALS INC. (US) | 1999-03-23 | — | — | US | claimed |
| CN-86108433-A | Polymer/liquid crystal composition semi-permeable membranes and using method thereof | — | 1987-07-29 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12233034-B2 | Formulations for epidermal repair | KRT18, CUTA, DSG1 | POLA1 2900/4885CYP46A1 1451/4885USP2 1927/4885 |
| US-20180289642-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | KRT18, CUTA, DSG1 | POLA1 3060/4885CYP46A1 1702/4885USP2 1921/4885 |
| US-20160184245-A1 | FORMULATIONS FOR EPIDERMAL REPAIR | KRT18, CUTA, DSG1 | POLA1 2900/4885CYP46A1 1451/4885USP2 1927/4885 |
| US-20060115445-A1 | Compositions for treating keratin materials comprising electrophilic monomers and liquid crystal agents | KRT18, PRKDC, CUTA | POLA1 1396/4885CYP46A1 3561/4885USP2 2505/4885 |
| US-20220031640-A1 | FORMULATIONS FOR EPIDURAL REPAIR | CUTA, EPHB1, EPHB2 | POLA1 4110/4885CYP46A1 912/4885USP2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.